2022
High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharaoh P, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0977-a.2021. PMID: 34789471, PMCID: PMC9281656, DOI: 10.1158/1055-9965.epi-21-0977.Peer-Reviewed Original ResearchConceptsOvarian cancer survivalCox proportional hazards modelProportional hazards modelCancer survivalOvarian cancerRisk scoreHazards modelNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useMenopausal hormone therapy useEnvironmental tobacco smoke exposureInvasive epithelial ovarian cancerHormone therapy usePelvic inflammatory diseaseInflammation-related factorsPolycystic ovarian syndromeTobacco smoke exposureBody mass indexRisk of deathEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancer diagnosisHigh death rateAspirin useOvarian syndrome
2020
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regression